ATE308998T1 - Langwirkende arzneistoffe und diese enthaltende arzneimittel - Google Patents

Langwirkende arzneistoffe und diese enthaltende arzneimittel

Info

Publication number
ATE308998T1
ATE308998T1 AT97933828T AT97933828T ATE308998T1 AT E308998 T1 ATE308998 T1 AT E308998T1 AT 97933828 T AT97933828 T AT 97933828T AT 97933828 T AT97933828 T AT 97933828T AT E308998 T1 ATE308998 T1 AT E308998T1
Authority
AT
Austria
Prior art keywords
peptide
long
hirudin
conjugates
products containing
Prior art date
Application number
AT97933828T
Other languages
German (de)
English (en)
Inventor
Matityahu Fridkin
Yoram Shechter
Eytan Gershonov
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE308998T1 publication Critical patent/ATE308998T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97933828T 1996-08-07 1997-08-05 Langwirkende arzneistoffe und diese enthaltende arzneimittel ATE308998T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11902996A IL119029A0 (en) 1996-08-07 1996-08-07 Long-acting drugs and pharamaceutical compositions comprising them
PCT/IL1997/000265 WO1998005361A2 (en) 1996-08-07 1997-08-05 Long-acting drugs and pharmaceutical compositions comprising them

Publications (1)

Publication Number Publication Date
ATE308998T1 true ATE308998T1 (de) 2005-11-15

Family

ID=11069166

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97933828T ATE308998T1 (de) 1996-08-07 1997-08-05 Langwirkende arzneistoffe und diese enthaltende arzneimittel

Country Status (18)

Country Link
US (1) US6504005B1 (enExample)
EP (1) EP1019089B1 (enExample)
JP (1) JP4416184B2 (enExample)
KR (1) KR20000029806A (enExample)
CN (1) CN1227501A (enExample)
AT (1) ATE308998T1 (enExample)
AU (1) AU725468B2 (enExample)
BR (1) BR9711045A (enExample)
CA (1) CA2261835C (enExample)
CZ (1) CZ36999A3 (enExample)
DE (1) DE69734607T2 (enExample)
DK (1) DK1019089T3 (enExample)
ES (1) ES2252787T3 (enExample)
HU (1) HUP0000809A2 (enExample)
IL (3) IL119029A0 (enExample)
NO (1) NO990518L (enExample)
NZ (1) NZ333845A (enExample)
WO (1) WO1998005361A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139400A0 (en) * 2000-11-01 2001-11-25 Yeda Res & Dev Long-acting cytokine derivatives and pharmaceutical compositions comprising them
AU3938402A (en) * 2000-12-13 2002-06-24 Lilly Co Eli Chronic treatment regimen using glucagon-like insulinotropic peptides
WO2003034988A2 (en) * 2001-10-19 2003-05-01 Idexx Laboratories, Inc. Injectable compositions for the controlled delivery of pharmacologically active compound
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
JP4033382B2 (ja) * 2002-04-08 2008-01-16 久光製薬株式会社 インスリン投与装置
WO2004064972A2 (en) * 2003-01-16 2004-08-05 Hk Pharmaceuticals, Inc. Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
PL1620118T3 (pl) * 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
ES2278314T3 (es) * 2003-04-17 2007-08-01 Jallal Messadek Formulaciones orales para la liberacion controlada de la betaina.
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
US7282487B2 (en) * 2004-10-28 2007-10-16 Idexx Laboratories Method for treating bacterial infections in horses or pigs with tilmicosin
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
ATE540690T1 (de) * 2005-04-27 2012-01-15 Jallal Messadek Insulinkombinationen
ES2371361T3 (es) * 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
ES2672526T3 (es) 2008-06-26 2018-06-14 Prolynx Llc Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas
EP2344200A2 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
PL2431741T3 (pl) * 2008-10-21 2014-01-31 Baxalta Inc Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro)
JP4959005B2 (ja) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
CN102413843A (zh) 2009-03-05 2012-04-11 阿森迪斯药物股份有限公司 干扰素α载体前药
WO2011013128A2 (en) 2009-07-31 2011-02-03 Yeda Research And Development Co. Ltd. Vectors for delivery of neurotherapeutics to the central nervous system
ES2584381T3 (es) * 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
EP2490378B1 (en) 2011-02-18 2014-07-09 NTT DoCoMo, Inc. Apparatus and method for determining a control unit using feasibility requests and feasibility responses
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
KR102092206B1 (ko) 2011-06-02 2020-03-24 옵코 바이오로직스 리미티드 장기-작용성 glp-1/글루카곤 수용체 작용제
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
EA201492269A1 (ru) 2012-06-04 2016-02-29 Опко Байолоджикс Лтд. Пегилированные варианты oxm
US20150111820A1 (en) 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
CA3129576A1 (en) 2019-02-11 2020-08-20 Opko Biologics Ltd. Long-acting glp-2 analogs
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
CA3153644A1 (en) 2019-09-30 2021-04-08 Beijing Xuanyi Pharmasciences Co., Ltd. Protein-macromolecule conjugates and methods of use thereof
CN113773398B (zh) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 一种德谷胰岛素衍生物及其应用
CN117551008B (zh) * 2023-11-10 2025-10-17 沈阳药科大学 一种去铁胺偶联物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194729C (nl) 1986-10-13 2003-01-07 Novartis Ag Werkwijze voor de bereiding van peptidealcoholen via vaste fase.
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US6313094B1 (en) * 1990-12-11 2001-11-06 Japan Energy Corporation β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
JPH0687887A (ja) * 1992-08-19 1994-03-29 Upjohn Co:The ペプチドのエナミン誘導体およびそれをプロドラッグとして含有するペプチド製剤
CA2142985A1 (en) 1993-06-25 1995-01-05 Kenji Shibata Endothelin-antagonizing peptide
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
AU1919595A (en) 1994-02-09 1995-08-29 Brigham And Women's Hospital Gel-forming polypeptide derivatives
DE4437604A1 (de) * 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
AU5377296A (en) * 1995-03-30 1996-10-16 Southpac Trust International, Inc. Self-erecting container which is collapsible to be substanti ally flat
US5688992A (en) 1995-03-31 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof
US5846934A (en) * 1996-02-20 1998-12-08 American Cyanamid Company Pure somatostatin antagonist and methods of use thereof
US6057297A (en) * 1996-08-06 2000-05-02 Polifarma S.P.A. Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof

Also Published As

Publication number Publication date
IL128274A0 (en) 1999-11-30
ES2252787T3 (es) 2006-05-16
CN1227501A (zh) 1999-09-01
IL119029A0 (en) 1996-11-14
AU725468B2 (en) 2000-10-12
CA2261835C (en) 2008-07-29
JP2000515542A (ja) 2000-11-21
NO990518L (no) 1999-04-06
DK1019089T3 (da) 2006-03-13
JP4416184B2 (ja) 2010-02-17
KR20000029806A (ko) 2000-05-25
CZ36999A3 (cs) 1999-07-14
WO1998005361A2 (en) 1998-02-12
WO1998005361A3 (en) 1998-06-18
DE69734607T2 (de) 2006-08-03
IL128274A (en) 2006-08-01
HUP0000809A2 (hu) 2000-11-28
EP1019089A2 (en) 2000-07-19
NO990518D0 (no) 1999-02-04
EP1019089B1 (en) 2005-11-09
AU3706097A (en) 1998-02-25
CA2261835A1 (en) 1998-02-12
DE69734607D1 (de) 2005-12-15
BR9711045A (pt) 1999-08-17
NZ333845A (en) 2000-09-29
US6504005B1 (en) 2003-01-07

Similar Documents

Publication Publication Date Title
ATE308998T1 (de) Langwirkende arzneistoffe und diese enthaltende arzneimittel
KR960702323A (ko) 폴리머를 사용하는 비타민 b₁₂ 흡수시스템의 증폭 (amplification of the vitamin b₁₂ uptake system using polymers)
DE68912232D1 (de) Konjugate zytotoxischer Arzneimittel.
NL194828B (nl) Somatostatinepeptiden, alsmede dergelijke somatostatinepeptiden bevattende farmaceutische preparaten.
RU94028890A (ru) Композиции производных циклодекстрина, композиции, содержащие лекарство и производные циклодекстринов
IL110978A0 (en) 17beta -anilide-4-aza- 5alpha -androst-1-en-3-one derivative, its preparation and pharmaceutical co mposition containing it
IT8947823A0 (it) Derivati peptidici, loro preparazione e loro impiego come medicamenti
ATE164843T1 (de) Naphthalinderivate, ihre herstellungsverfahren und zwischenprodukte dafür, und diese enthaltende pharmazeutische zusammensetzungen
EP1004318A3 (en) Cyclodextrin composition
IL111533A0 (en) Quinoxalinedione derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
ES2193272T3 (es) Conjugados peptidicos, su utilizacion como medicamento y composiciones que los contienen.
DE69627691D1 (de) Aus thymischen hormonen abstammende peptid konjugierte, deren verwendung als medikamente und aus deren enthaltende zusammensetzungen
DE69724453D1 (de) Camptothecine analoga, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen
IL98769A (en) Synthetic peptides, mixtures thereof, methods utilizing the same for detecting hiv antibodies and pharmaceutical compositions containing the same
AU5433496A (en) Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
DE69524971D1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
DE68907392D1 (de) Dysmnesie modifizierende arzneimittel.
AU7209594A (en) Anti-inflammatory peptides
IL100853A0 (en) Msh peptide derivatives,their preparation and pharmaceutical compositions comprising them
AU2387592A (en) Cyclic hexapeptides as tachyquinin antagonists, their preparation and pharmaceutical compositions thereof
DE69425860D1 (de) Hepatotropische konjugaten von antivirale arzneimittel, traeger und pharmazeutische zusammensetzungen
IT1237783B (it) Derivati di ferro-albumina biodisponibile, loro procedimento di preparazione e relative composizioni farmaceutiche.
DE69029259D1 (de) Polypeptid, dessen herstellung, und dieses polypeptid enthaltende pharmazeutische verbindungen und kosmetika
BR9603253B1 (pt) derivado de camptotecina e composiÇço farmacÊutica compreendendo o mesmo.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1019089

Country of ref document: EP